10x Genomics, Inc. (NASDAQ:TXG) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET

Company Participants

Cassie Corneau - Head, Investor Relations & Strategic Finance

Serge Saxonov - Chief Executive Officer & Co-Founder

Justin McAnear - Chief Financial Officer

Conference Call Participants

Tejas Savant - Morgan Stanley

Dan Arias - Stifel

Patrick Donnelly - Citi

Kyle Mikson - Canaccord Genuity

Dan Brennan - Cowen

Julia Qin - JPMorgan

Michael Ryskin - Bank of America

Matt Sykes - Goldman Sachs

Operator

Good evening and thank you for attending today's 10x Genomics Third Quarter 2022 Earnings Conference Call. My name is Daniel and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for question-and-answer session at the end. [Operator Instructions]

I would now like to pass the conference over to our host Cassie Corneau, Head of Investor Relations and Strategic Finance. Cassie please proceed.

Cassie Corneau

Thank you and good afternoon everyone. Earlier today, 10x Genomics released financial results for the third quarter ended September 30th, 2022. If you have not received this news release or if you would like to be added to the company's distribution list, please send an e-mail to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website 10xgenomics.com for at least 45 days following this call.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated and you should not place undue reliance on forward-looking statements.

Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time-to-time with the Securities and Exchange Commission.

10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements whether because of new information future, events, or otherwise.

Joining the call today are Serge Saxonov, our CEO and Co-Founder; and Justin McAnear, our Chief Financial Officer.

With that, I will now turn the call over to Serge.

Serge Saxonov

Thanks Cassie. Good afternoon and thank you for joining us. Today, I will start with a brief overview of our performance during the third quarter. Next, I will discuss our progress momentum and the exciting opportunities we have ahead in each of our three platforms. I'll touch on what we're seeing in the market from a commercial perspective and then hand the call over to Justin for a more detailed look at our financials, business trends, and outlook as we get ready to close out the year.